FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer
The approval is based on phase 3 trial data showing prolonged event-free survival with the pembrolizumab regimen vs neoadjuvant chemotherapy alone for previously untreated stage II or III TNBC.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Hematology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy